Professional Documents
Culture Documents
DOI 10.1007/s00384-012-1552-1
ORIGINAL ARTICLE
Our aim was to test in a double-blinded, randomised The following medications were permitted during the course
placebo-controlled study the effects of a commercially avail- of the study, as long as they had been used at a constant
able symbiotic mixture in IBS patients. dosage and were commenced at least 1 month prior to the
Int J Colorectal Dis (2013) 28:349–358 351
start of the 2-week run-in period: birth control pill or depot placebo (CaDi Group, Rome, Italy) comparable in colour,
intramuscular contraceptive preparation, oestrogen–proges- texture and taste to the symbiotic mixture. The patients were
terone replacement therapy, L-thyroxine, low-dose antide- instructed to ingest the investigational powder preparation
pressants (up to 25 mg day−1 of amitriptyline, nortriptyline twice daily, preferably in the morning and in the evening far
or selective serotonin reuptake inhibitor) or antihyperten- from meals, dissolving it in water.
sives in the diuretic, angiotensin-converting enzyme inhib-
itor or angiotensin II inhibitor classes. Assessment of symptoms and bowel functions
0 14 42
days
10 withdrew consent
1 concomitant acute disease
1 PPI therapy
2 failed sev criteria
1 pregnant
68 randomized
34 symbiotic 34 placebo
2 drop-outs 2 drop-outs
1 protocol violation 2 lack of effect
1 lack of effect
32 symbiotic 32 placebo
354 Int J Colorectal Dis (2013) 28:349–358
Symbiotic Placebo The compliance was >95 % in both groups as analysed from
the study diaries. Five of the 64 participants (one in placebo
N 32 32 and four in the treated group) required antibiotic therapy
Gender, n (%) 22 (69) 19 (59) during the study period for infection (cystitis, upper respi-
Age 36.6±2.2 40.8±2.2 ratory infection and prophylaxis for dental work) and ad-
FBDSI 61.5±6.9 63.7±7.3 hered to protocol instructions. One patient from each
Predominant bowel habit treatment group used a loperamide tablet (average use, two
Diarrhoea, n (%) 9 (28.1) 14 (43.8) tablets; range 1–3) as predefined rescue medication for
Constipation, n (%) 13(40.6) 12 (37.5) severe diarrhoea during the 6-week trial. Other medications
Mixed, n (%) 10 (31.3) 4 (12.5) were: milk of magnesia (two patients for 1 day), paraceta-
Undetermined, n (%) 0 (0.0) 2 (6.3) mol (two patients for 2 days), prednisone (one patient for
Bloating VAS score 40.7±3.7 42.6±2.8 5 days), budesonide inhaler (one patient for 6 days) and
Flatulence VAS score 36.4±2.9 35.4±2.7 ketoprofen (one patient for 1 day).
proportion of days with the sense of incomplete evacuation There were no adverse events noted with the use of this
p00.552). symbiotic mixture and/or placebo treatment.
Quality and quantity of food intake were unchanged along the In the run-in period, no significant differences were
entire study: run-in and randomisation period (data not shown). found in total, right, left and rectosigmoid transit time
Fig. 3 VAS scores of bloating, flatulence, abdominal pain and urgency during the run-in and treatment period in symbiotic and placebo groups.
(Mean values±SE; repeated-measures ANCOVA, p<0.05)
Int J Colorectal Dis (2013) 28:349–358 355
only strain that could show any positive effect upon the colonic transit time significantly correlated with the increase
symptoms, in two appropriately designed studies [10]. An- in stool consistency measured by Bristol Scale score. This
other one, analysing the continuous data, demonstrated that may result in reduced aborad movement of stool and, pos-
combinations of probiotics improved symptoms in patients sibly, the reduced flatulence [7].
with IBS, and in addition, higher quality studies reported a Although it seems biologically plausible that modifica-
more modest treatment effect, compared to lower quality tion of the gut flora could have an effect on IBS-related
studies [11]. symptoms such as the flatulence sensation by modifying gas
Our finding, of a significant decrease in the severity of production (colonic milieu) and gut transit, further studies
flatulence in IBS patients treated with the symbiotic mixture are needed to explore the mechanism of the observed re-
compared to the IBS patients treated with the placebo over a tarded transit of stool and the potential effects on colonic
4-week period of treatment, suggests a beneficial effect of sensation and colonic fermentation of nutrients reaching the
this particular combination of prebiotics and probiotic in colon. In the literature, several mechanisms have been sug-
IBS patients. However, contrary to our hypothesis, the pres- gested to explain the efficacy of probiotics in IBS, such as
ent study was not able to show an improvement of other the influence of intestinal luminal environment, the mainte-
investigated outcomes, especially those of the primary out- nance of epithelial and mucosal barrier function and the
come (global satisfactory relief in symptoms of bloating and modulation of mucosal or systemic immune system includ-
flatulence). This result may be related to the intrinsic limi- ing both innate and adaptive immune systems [30–32].
tations of the study design which was the first study on this Although it might be too early to make a conclusion of
symbiotic mixture, with a small number of patients that whether these mechanisms could be adapted to the patho-
leads to the lack of statistical power (type 2 error) as well genesis of IBS, there is, however, a growing body of evi-
as to the inclusion of a heterogeneous IBS population. The dence that supports the association of gut inflammation/
primary outcome, furthermore, is a multidimensional out- immunity and IBS and that define the roles of probiotics
come that is influenced by a number of factors, including in the pathogenesis of IBS. Another important issue is that
coping mechanisms and psychological status, which may in the symbiotic mixture administered in the present study,
not be directly related to symptoms severity [29]. It is there are also prebiotics and their exact role in IBS remains
noteworthy that most domains in the SF-36 QoL question- unclear due to the paucity of trials evaluating their treatment
naire have improved in the active group with symbiotic efficacy [33]. Prebiotics, at least in theory, may globally
treatment but only a few in the placebo group. enhance the functions of probiotics, augment the effects of
There are no current studies available that could prove beneficial commensal bacteria of the gut and assist in the
unambiguously the mode of action of probiotics, which can creation of an inhospitable environment for the proliferation
be clearly linked to the improvement of IBS and its symp- of pathogenic bacteria [34]. As shown in Fig. 3, it is inter-
toms. As an attempt to investigate the possible effects of the esting that flatulence seems to worsen initially in the sym-
symbiotic mixture on IBS symptoms, transit time was stud- biotic group and then it improves. This is potentially an
ied. At the end of treatment, patients treated with the sym- important point of interest. In fact, prebiotic, such as inulin,
biotic mixture showed a lengthening in rectosigmoid transit could initially cause an increase in flatulence delivering, as
time that just failed to reach a statistical significance. The it does, unabsorbed carbohydrate to colonic bacteria.
Int J Colorectal Dis (2013) 28:349–358 357
syndrome? A prospective controlled study with emphasis on stool confounded by baseline symptom severity and do not accurately
form. Gut 32:73–79 reflect symptom improvement. Am J Gastroenterol 101(5):1057–
22. Metcalf AM, Phillips SF, Zinsmeister AR et al (1987) Simplified 1065
assessment of segmental colonic transit. Gastroenterology 30. Ng SC, Hart AL, Kamm MA et al (2009) Mechanisms of action of
92:40–47 probiotics: recent advances. Inflamm Bowel Dis 15:300–310
23. Apolone G, Mosconi P (1998) The Italian SF-36 Health Survey: 31. Forsythe P, Bienenstock J (2010) Immunomodulation by commensal
translation, validation and norming. J Clin Epidemiol 51:1025–1036 and probiotic bacteria. Immunol Invest 39:429–448
24. Gawrońska A, Dziechciarz P, Horvath A, Szajewska H (2007) A 32. Ohland CL, Macnaughton WK (2010) Probiotic bacteria and
randomized double-blind placebo-controlled trial of Lactobacillus intestinal epithelial barrier function. Am J Physiol Gastrointest
GG for abdominal pain disorders in children. Aliment Pharmacol Liver Physiol 298:G807–G819
Ther 25(2):177–184 33. Preidis GA, Versalovic J (2009) Targeting the human micro-
25. Kajander K, Hatakka K, Poussa T, Färkkilä M, Korpela R (2005) biome with antibiotics, probiotics, and prebiotics: gastroen-
A probiotic mixture alleviates symptoms in irritable bowel syn- terology enters the metagenomics era. Gastroenterology
drome patients: a controlled 6-month intervention. Aliment Phar- 136:2015–2031
macol Ther 22(5):387–394 34. Paineau D, Payen F, Panserieu S et al (2008) The effects of regular
26. Ringel Y, Williams RE, Kalilani L et al (2009) The prevalence, consumption of short-chain fructo-oligosaccharides on digestive
characteristics and impact of bloating symptoms in patients with comfort of subjects with minor functional bowel disorders. Br J
irritable bowel syndrome. Clin Gastroenterol Hepatol 7:68–72 Nutr 99(2):311–318
27. Parkes GC, Sanderson JD, Whelan K (2010) Treating irritable bowel 35. Cattivelli D, Soldi S, Elli M, et al. (2005) Assessing a multi
syndrome with probiotics: the evidence. Proc Nutr Soc 69:187–194 strain symbiotic dietary supplement. 3rd Probiotics, Prebiot-
28. Chang JY, Talley NJ (2010) Current and emerging therapies in ics and New Foods 4–6 Sep 2005, Urbaniana University,
irritable bowel syndrome: from pathophysiology to treatment. Rome
Trends Pharmacol Sci 31:326–334 36. Tsuchiya J, Barreto R, Okura R et al (2004) Single blind follow up
29. Whitehead WE, Palsson OS, Levy RL et al (2006) Reports of ‘satis- study on the effectiveness of a symbiotic preparation in irritable
factory relief’ by IBS patients receiving usual medical care are bowel syndrome. Chin J Dig Dis 5:169–174